Registry update — unassessed
A Phase II Randomized Double-Blind Placebo-Controlled Study of Fisetin to Improve Physical Function in Breast Cancer Survivors
Trial registry update: RECRUITING. No results reported in the supplied registry record.
RCTRoutine significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Jul 17, 2026 · Discovered: Sep 15, 2026 · Assessed: — · Historical research backfill
What it does not prove
- The abstract reports rationale and study design but contains no results, so effectiveness cannot be assessed from this material
- Even if results exist, a phase II trial cannot establish clinical benefit or whether fisetin works in the broader breast cancer survivor population
- The mechanism linking senescent cells to post-chemotherapy dysfunction remains theoretical in this specific population
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Women who have received chemotherapy for stage I-III breast cancer, described as postmenopausal in the rationale.
- Primary outcome
- Improvement in physical function
- Effect size
- —
- Significance
- Not reported
- Journal
- Jonsson Comprehensive Cancer Center
- Published
- Jul 17, 2026
Sources
Primary source
- Jonsson Comprehensive Cancer Center ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
This phase II trial tests whether fisetin works to improve physical function in women who have received chemotherapy for stage I-III breast cancer treatment.
Fisetin is a naturally occurring substance that is found in strawberries and other foods.
Fisetin eliminates cells that have undergone a process called senescence.
Studies have shown that chemotherapy causes a build-up of these senescent cells.
Giving fisetin may eliminate senescent cells and improve physical function in postmenopausal women who have received chemotherapy for breast cancer.
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.